Statins Exert the Pleiotropic Effects Through Small GTP-Binding Protein Dissociation Stimulator Upregulation With a Resultant Rac1 Degradation

Shin-ichi Tanaka, Yoshihiro Fukumoto, Kotaro Nochioka, Tatsuro Minami, Shun Kudo, Nobuyuki Shiba, Yoshimi Takai, Carol L. Williams, James K. Liao, Hiroaki Shimokawa

Objective—The pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) independent of cholesterol-lowering effects are thought to be mediated through inhibition of the Rho/Rho-kinase pathway. However, we have previously demonstrated that the pleiotropic effects of regular-dose statins are mediated mainly through inhibition of the Rac1 signaling pathway rather than the Rho/Rho-kinase pathway, although the molecular mechanisms of the selective inhibition of the Rac1 signaling pathway by regular-dose statins remain to be elucidated. In this study, we tested our hypothesis that small GTP-binding protein GDP dissociation stimulator (SmgGDS) plays a crucial role in the molecular mechanisms of the Rac1 signaling pathway inhibition by statins in endothelial cells.

Approach and Results—In cultured human umbilical venous endothelial cells, statins concentration-dependently increased SmgGDS expression and decreased nuclear Rac1. Statins also enhanced SmgGDS expression in mouse aorta. In control mice, the protective effects of statins against angiotensin II–induced medial thickening of coronary arteries and fibrosis were noted, whereas in SmgGDS-deficient mice, the protective effects of statins were absent. When SmgGDS was knocked down by its small interfering RNA in human umbilical venous endothelial cells, statins were no longer able to induce Rac1 degradation or inhibit angiotensin II–induced production of reactive oxygen species. Finally, in normal healthy volunteers, statins significantly increased SmgGDS expression with a significant negative correlation between SmgGDS expression and oxidative stress markers, whereas no correlation was noted with total or low-density lipoprotein-cholesterol.

Conclusions—These results indicate that statins exert their pleiotropic effects through SmgGDS upregulation and reduced oxidative stress in animals and humans. (Arterioscler Thromb Vasc Biol. 2013;33: 1591-1600.)

Key Words: Rac ■ reactive oxygen species ■ Rho ■ small GTP-binding protein GDP dissociation stimulator ■ statins

3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are potent cholesterol-lowering drugs widely used in clinical practice for primary and secondary prevention of coronary artery disease.1,2 Furthermore, the beneficial cardiovascular effects of statins, beyond their lipid-lowering action (the so-called pleiotropic effects), have attracted much attention.3,4 The pleiotropic effects of statins could be mediated by reduced synthesis of the isoprenoids that are responsible for the post-translational modulation of intracellular proteins.1 Because membrane localization and GTPase activity of small GTP-binding proteins (eg, Rho, Rac, and Ras) are dependent on isoprenylation, the pleiotropic effects of statins have been considered to be mediated by inhibition of those small GTP-binding proteins.5,6 However, the specific cellular GTPase target protein(s) of statins still remains to be elucidated.

We have recently demonstrated that regular-dose statins (atorvastatin and pravastatin, 20 mg/d for 1 week) significantly inhibit Rac1, but not RhoA/Rho-kinase, activity in circulating leukocytes in normal healthy volunteers.7 Rac1 plays a crucial role in generating reactive oxygen species (ROS) and is an important mediator of cardiovascular hypertrophy.8 In mouse models of angiotensin II (AngII)– and pressure overload–induced cardiovascular hypertrophy, it was reported that simvastatin inhibits Rac1-mediated ROS production in the heart and vascular smooth muscle.9,10 These findings are
further supported by the analysis of failing human heart tissues, where increased ROS generation is associated with increased Rac1 activity, both of which are attenuated by statins. More interestingly, it has been reported that the protective effects of regular-dose pitavastatin are noted in endothelial nitric oxide synthase–deficient (eNOS−/−) mice. Thus, we considered that the pleiotropic effects of regular-dose statins are mediated mainly through inhibition of the Rac1 pathway rather than the other pathway. However, the molecular mechanisms of the selective inhibition of the Rac1 signaling pathway by regular-dose statins remain to be elucidated.

To elucidate the molecular mechanisms of the preferential inhibition of the Rac1 signaling pathway by regular-dose statins, we hypothesized that the small GTP-binding protein GDP dissociation inhibitor–related protein SmgGDS interacts with the small GTPase C-terminal polybasic region. Importantly, the polybasic region of Rac1, but not that of RhO A, has a functional nuclear localization signal sequence and Rac1 with a functional nuclear localization signal accompanies SmgGDS into the nucleus and is degraded by the proteasome system. In the present study, we thus tested our hypothesis that SmgGDS plays a crucial role in the molecular mechanisms of the pleiotropic effects of statins in animals and humans.

Materials and Methods

Materials and Methods are available in the online-only Supplement.

Transfection of Human Umbilical Venous Endothelial Cells With Small Interfering RNA

Multiple small interfering RNA (siRNA) duplexes for SmgGDS were purchased from Qiagen. Multiple siRNA duplexes were transfected and tested for maximal and specific suppression of their target protein as previously described. A functional nontargeting siRNA that was bioinformatically designed by Qiagen was used as a control. Human umbilical venous endothelial cells (HUVECs) were transfected with HiPerFect Transfection Reagent (Qiagen) with either 10 nmol/L mock siRNA or 10 nmol/L siRNA specific for SmgGDS. After 72 hours post-transfection, the cells were analyzed by Western blot or ROS analysis.

ROS Analysis

Intracellular ROS production in HUVECs was measured as previously described. We treated HUVECs with AngII (1 μmol/L, Wako) for 3 hours at 37°C in 5% CO2, washed them with PBS, and loaded them with 2,7-dichlorofluorescein diacetate (5 μmol/L, Cayman) for 30 minutes at 37°C to reveal the presence of ROS as green fluorescence (488 nm) by fluorescence microscopy (BIOREVO, Keyence). The relative fluorescence intensity was measured by BZ-II analyzer (Keyence) software.

Analysis of Medial Thickening and Perivascular Fibrosis of Mouse Coronary Arteries

We performed all mouse experiments in accordance with experimental protocols approved by the Animal Care and Use Committee of the Tohoku University Graduate School of Medicine. We used the AngII-infused cardiovascular hypertrophy model to assess the effect of SmgGDS deficiency on the pleiotropic effects of regular-dose statins. We infused AngII (2.0 mg/kg per day) or saline for 2 weeks in 10-week-old male SmgGDS−/− littermate control mice and SmgGDS−/− mice. We dissolved AngII in sterile saline and infused it via an osmotic mini-pump (Alzet model 2002, Alze Corp). We anesthetized the animals with isoflurane and placed the pump into the subcutaneous space of isoflurane-anesthetized mice through a small incision in the back that was closed by suturing. Both the AngII-infused and saline-infused mice were administered either statin or placebo treatment by gavage every day for 2 weeks. All incision sites healed rapidly without any infection. Systolic blood pressure was measured using a noninvasive tail-cuff system (MK-2000, Muromachi) at 2 weeks after pump implantation. Plasma lipids (triglycerides, total cholesterol, and low-density lipoprotein (LDL)- and high-density lipoprotein-cholesterol) were analyzed with high-performance liquid chromatography system by Skylight Biotech. Histological studies were performed for the determination of medial thickness and fibrosis of coronary arteries, as previously reported.

Human Study

This protocol was approved by the Human Research Committee of the Tohoku University Graduate School of Medicine, and 20 normal healthy human volunteers participated after written consent was obtained (Table II in the online-only Data Supplement). The volunteers received pravastatin (20 mg/d) or atorvastatin (20 mg/d) orally for 2 weeks in a randomized crossover manner with a 2-week washout interval. The 2-week interval is enough to restore lipid profiles to prestatin treatment levels. Leukocytes were isolated according to the method previously described with slight modification.

Statistical Analysis

Comparisons of parameters between 2 groups were performed with the unpaired Student t test. Statistical analysis was performed by 1-way ANOVA followed by Dunnett test for multiple comparisons. Statistical significance was evaluated with JMP 8 (SAS Institute). A P<0.05 was considered to be statistically significant.

Results

Statins Upregulate SmgGDS in HUVECs and Mouse Aorta

To examine whether SmgGDS levels are actually increased by statins, we first examined the effects of 2 statins (atorvastatin, 10 and 30 μmol/L, and pitavastatin, 1 and 10 μmol/L) on the SmgGDS expression in cultured HUVECs after 24 hours treatment. These 2 statins increased SmgGDS expression in HUVECs in a concentration-dependent manner (Figure 1A and 1B). Similarly, these 2 statins also increased SmgGDS expression in human coronary arterial endothelial cells (Figure 1A and 1B in the online-only Data Supplement). Furthermore, to explore whether the upregulation of SmgGDS noted in vitro exist in vivo, we examined the effect of statins on SmgGDS expression in mouse aorta treated with 2 statins (atorvastatin, 10 mg/kg per day and pitavastatin, 50 mg/kg per day) for 1 week. These 2 statins increased SmgGDS expression in mouse aorta (Figure 1C). This is the novel finding that statins exert class effects to increase SmgGDS expression levels in vitro and in vivo.

No Cardioprotective Effects of Statins in SmgGDS-Deficient Mice

Next, we examined the effects of statins on AngII-induced medial thickening and perivascular fibrosis of coronary arteries in mice in vivo. It has been reported that statins attenuate AngII-induced cardiovascular hypertrophy in wild-type mice without changes in blood pressure or
plasma cholesterol levels. Thus, this effect of statins is highly likely to depend on their pleiotropic effects. AngII was administered to heterozygous SmgGDS-deficient mice (SmgGDS+/−) and littermate (SmgGDS +/+) mice with an infusion pump for 2 weeks. Systolic blood pressure was elevated in both SmgGDS+/− and littermate mice, and plasma total and LDL-cholesterol levels tended to increase (Table I in the online-only Data Supplement). There was no significant difference in blood pressure or plasma lipid profiles between the vehicle and the statin groups (Table I in the online-only Data Supplement). Analysis of microscopic examination of coronary artery sections revealed that AngII caused accelerated medial thickening (Figure 1D and 1E) and perivascular fibrosis of coronary arteries (Figure 1D and 1F). In littermate mice, the protective effects of statins against AngII-induced medial thickening of coronary arteries and fibrosis were noted, whereas in SmgGDS+/− mice, the protective effects of statins were absent (Figure 1D–1F).
Statins Upregulate SmgGDS in HUVECs Through the Phosphoinositide-3-Kinase/Akt/Glycogen Synthase Kinase-3β Pathway

Next, we analyzed the mechanisms by which statins increase SmgGDS expression in HUVECs. It has been reported that statins increase β-catenin that is a member of the armadillo protein family like SmgGDS.24 This is achieved through statin-mediated inhibition of glycogen synthase kinase-3β (GSK-3β) and thereby inhibition of β-catenin phosphorylation.25,26 Because phosphorylated β-catenin is more prone to ubiquitination and degradation, inhibition of β-catenin phosphorylation increases the stability of β-catenin. It was previously shown that the selective GSK-3β inhibitor, SB216763, also increases the β-catenin expression level.26 Thus, we examined the possible enhancing effect of SB216763 on SmgGDS expression in HUVECs. As we expected, SB216763 increased SmgGDS expression in a concentration-dependent manner (Figure 2A). Similar results were obtained with lithium, another GSK-3β inhibitor (data not shown). This increase in SmgGDS when GSK-3β is inactivated by SB216763 or lithium is consistent with the presence of several putative GSK-3β phosphorylation sites in SmgGDS identified by the eukaryotic linear motif program (http://elm.eu.org). This increase in SmgGDS by statins was reversed by either phosphoinositide-3-kinase (PI3K) inhibitor (LY294002), Akt inhibitor (MK2206), or AKT 1/2 inhibitor (Figure 2B and 2C). Interestingly, this increase in SmgGDS in response to SB216763 was not reversed by LY294002, MK2206, or AKT 1/2 inhibitor (Figure 2D).

Next, we examined whether mevalonate and isoprenoids (farnesyl pyrophosphate and geranylgeranyl pyrophosphate), both of which are important products of the cholesterol biosynthesis pathway,27 mediate the statin-induced SmgGDS upregulation. Because it is known that the reduced mevalonate biosynthesis is one of the mechanisms of activation of the PI3K/Akt pathway by statins,28 we hypothesized that statins activate PI3K/Akt pathway through mevalonate, which in turn inhibits GSK-3β. Importantly, mevalonate did not inhibit the statin-induced SmgGDS upregulation (Figure 3A). This may be explained by activation of Akt via an alternative pathway. It has been shown that Akt is activated by vascular endothelial growth factor (VEGF) and that Akt activation is not reversed by mevalonate.28 Furthermore, it has been reported that statins increase mRNA and protein expression levels of VEGF in HUVECs.29 We observed that statins upregulated VEGF, which was not reversed by mevalonate (Figure 3B). However, in the present study, because of several technical reasons, including the nonspecific effects of VEGF receptor inhibitors and the presence of VEGF in culture medium, we did not further examine the possible role of VEGF in the effects of statins. In addition, because farnesyl pyrophosphate and geranylgeranyl pyrophosphate control the post-translational modification of intracellular proteins and membrane localization and activity of small GTPase,30 they could play a central role in the pleiotropic effects of statins.31,32 Splice variants of SmgGDS also could control small GTPase prenylation and membrane localization.33 However, farnesyl pyrophosphate or geranylgeranyl pyrophosphate did not inhibit the upregulation of SmgGDS by statins (Figure 3C). We also demonstrated the increase in endothelial nitric oxide synthase expression as a positive control of drug treatments (Figure II and III in the online-only document).
Data Supplement). Thus, the enhancing effects of statins on SmgGDS expression are not mediated through reduction in these isoprenoids. Next, because it has been reported that guanine nucleotide exchange factor function is regulated by Rho-kinase, we examined whether the enhancing effects of SmgGDS by statins are mediated by the inhibitory effect of statins on the Rho-kinase pathway. However, a specific Rho-kinase inhibitor, hydroxyfasudil, did not increase SmgGDS expression (Figure 3D). Thus, the enhancing effects of statins on SmgGDS expression are not mediated through inhibition of the Rho-kinase pathway. Taken together, these results indicate that statins increase SmgGDS expression through inhibition of GSK-3β via the PI3K/Akt pathway.

Statins Reduce ROS Production via SmgGDS
To explore the effect of statins on Rac1 expression, we examined Rac1 protein expression levels in HUVECs after 24 hours treatment with statins. Atorvastatin significantly decreased total Rac1 level (Figure 4A), which was also the case with pitavastatin (Figure IVA in the online-only Data Supplement). Next, we examined the mechanism by which statins decrease Rac1 level. It was previously reported that Rac1 is degraded by the nuclear proteasome. Thus, we cotreated HUVECs with statins and a proteasome inhibitor, MG-132. As we expected, although atorvastatin significantly decreased nuclear Rac1 expression level, MG-132 inhibited the decrease in Rac1 expression by atorvastatin in the nucleus (Figure 4B). This was also the case with pitavastatin (Figure IVB in the online-only Data Supplement). RhoA and K-Ras were not detected in nuclear fraction (Figure VB in the online-only Data Supplement). We also measured cytosolic Rac1 expression after treatment with both MG-132 and statins, and confirmed that MG-132 did not increase cytosolic Rac1 expression (Figure VC in the online-only Data Supplement). Thus, statins preferentially enhance degradation of Rac1 through degradation by proteasomes in the nucleus.

We further examined the effect of statins on SmgGDS expression by using its siRNA in HUVECs. Densitometric analysis showed that SmgGDS expression levels were reduced by ≈85% after SmgGDS siRNA transfection, relative to mock siRNA-transfected cells (Figure V A in the online-only Data Supplement). In mock siRNA-transfected cells, atorvastatin decreased Rac1 expression in whole cells, whereas in SmgGDS siRNA–transfected cells, atorvastatin was no longer able to induce Rac1 degradation (Figure 4A). This was also
the case with pitavastatin (Figure IVA in the online-only Data Supplement). Thus, we were able to further confirm that statins enhance Rac1 degradation via SmgGDS. Furthermore, we examined the possible role of Rac1 degradation in mediating the pleiotropic effects of statins by evaluating the antioxidant effects of statins. It has been reported that statins decrease AngII-induced production of ROS.10,35 In mock siRNA–transfected cells, atorvastatin (1 μmol/L) decreased AngII-induced production of ROS, whereas in SmgGDS siRNA-transfected cells, atorvastatin was no longer able to inhibit AngII-induced production of ROS (Figure 4C and 4D). This was also the case with pitavastatin (0.1 μmol/L; Figure IVC and IVD in the online-only Data Supplement).

**Statins Upregulate SmgGDS in Humans**

Finally, we examined the effects of statins on SmgGDS expression in normal healthy volunteers, who received pravastatin and atorvastatin (20 mg/d each) orally for 2 weeks in a crossover manner with a 2-week washout period (Figure VI in the online-only Data Supplement). Both statins significantly reduced the serum levels of total cholesterol and LDL-cholesterol even in the normolipidemic volunteers, indicating the efficacy of the statin therapy (Table III in the online-only Data Supplement). SmgGDS expression in circulating polymorphonuclear leukocytes was significantly increased after the treatment with pravastatin or atorvastatin (Figure 5A). Importantly, both pravastatin (a hydrophilic stain) and atorvastatin (a lipophilic statin) exerted a comparable enhancing effect on SmgGDS expression in humans, indicating the class effect of statins to enhance SmgGDS level in humans. Furthermore, malondialdehyde-modified–LDL-cholesterol, one of the oxidative stress markers, was significantly decreased with the statin treatment (Table III in the online-only Data Supplement). Importantly, a significant negative correlation was noted between the extent of SmgGDS level and that of malondialdehyde–LDL-cholesterol level, whereas no such correlation was noted with total or LDL-cholesterol (Figure 5B–5E).

**Discussion**

To the best our knowledge, the present study provides the first direct evidence that SmgGDS plays a crucial role in the molecular mechanisms of the pleiotropic effects of statins through enhancement of intranuclear Rac1 degradation in animals and humans (Figure 6). Multiple processes may be involved in the effects of statins on SmgGDS. First, statins increase SmgGDS expression. Second, SmgGDS binds and transports Rac1 to the nucleus. Third, Rac1 is degraded by the nuclear proteasome system. Fourth, total Rac1 degradation causes reduced ROS production. Finally, this reduced ROS production exerts cardiovascular protective effects independent of cholesterol levels, that is, the pleiotropic effects of statins.
in circulating leukocytes in humans. In the present in vivo study, we used atorvastatin and pravastatin to address whether lipophilic and hydrophilic statins exert similar class effects. We have previously demonstrated the pharmacokinetic profiles of atorvastatin and pravastatin in rats, confirming that the plasma concentrations of the statins in rats were equivalent to their maximum concentrations (Cmax) in humans. Previous reports showed that both the Rho/Rho-kinase and Rac1 pathways are involved in the pathogenesis of cardiovascular diseases. In the present study, we tested our hypothesis that the pleiotropic effects of regular-dose statins are mediated through inhibition of the Rac1 signaling pathway but not that of the Rho/Rho-kinase signaling pathway. High-dose statins certainly suppress the Rho/Rho-kinase signaling pathway. In cultured endothelial cells, we noted that statins enhanced SmgGDS expression independent of mevalonate or Rho/Rho-kinase pathway, resulting in enhanced Rac1 degradation and reduced production of ROS. However, the role of Rac1 in the nucleus and the reason for its intranuclear degradation remain to be clarified. It has been reported that Rac1 activation is indispensable for nuclear localization of β-catenin during canonical Wnt signaling. Rac1 interacts with β-catenin and Dickkopf1 genes to control limb outgrowth in mice. Because β-catenin is a member of the armadillo protein family like SmgGDS, it is conceivable that nuclear translocation of Rac1 is necessary during fetal development. In SmgGDS−/− mice, we noted that the cardiovascular protective effects of statins were absent. Interestingly, the protective effects of statins against cardiovascular hypertrophy and diastolic dysfunction are noted even in eNOS−/− mice. Moreover, statin treatment ameliorated the high mortality rate in AngII-treated eNOS−/− mice associated with suppression of oxidative stress. It has been suggested that endothelial nitric oxide synthase activation through the Akt pathway is also important in the pleiotropic effects of statins. Alternatively, statins inhibit the transforming growth factor (TGF)-β1/Smad signaling pathway through suppression of oxidative stress. TGF-β1 is one of the most important proinflammatory molecules, and TGF-β1 overexpression in mice results in cardiac hypertrophy and fibrosis. On the contrary, in TGF-β1−/− deficient mice, AngII-induced cardiac hypertrophy is absent. These effects of statins are considered to be mediated by their pleiotropic effects. The present results suggest that statins exert their cardiovascular protective effects through endothelial nitric oxide synthase-independent pathway because the Rac1 signaling pathway is upstream of the ROS/TGF-β1/Smad signaling pathway.

In the present study, we used SmgGDS−/− mice because SmgGDS−/− mice die of heart failure shortly after birth, as a result of enhanced cardiomyocyte apoptosis triggered by cardiovascular overload but not developmental heart defects. In contrast, SmgGDS−/− mice are viable with no abnormal phenotypes, and there was no difference in AngII-induced increase in heart weight or blood pressure between SmgGDS−/− littermate mice. The reason why AngII-induced cardiovascular phenotype did not become more serious in SmgGDS−/− mice is unclear. However, the reduction in SmgGDS expression level in SmgGDS−/− mice may not be enough to worsen cardiovascular phenotype. Thus, SmgGDS−/− mice are suitable...
cholesterol-lowering effect in the present results in humans. cannot completely rule out the possible involvement of their statins through inhibition of Rac1 activation. In this study, we activation of superoxide production, which is inhibited by contributes to the pathogenesis of atrial fibrillation through because statins significantly reduced the serum levels of total volunteers, a consistent finding with previous reports, we noted with total or LDL-cholesterol. The present results was noted with total or LDL-cholesterol. The present results significant negative correlation between SmgGDS expression and oxidative stress markers, whereas no such correlation was noted with total or LDL-cholesterol. The present results are consistent with a previous report that statins inhibit ROS production through inhibition of Rac1 activity in the failing and oxidative stress markers, whereas no such correlation was noted with total or LDL-cholesterol. The present results are consistent with a previous report that statins inhibit ROS production through inhibition of Rac1 activity in the failing cardiovascular hypertrophy in both wild-type and β-catenin–mutant mice. In contrast, mice with stabilized β-catenin show decreased cardiac cross-sectional area at baseline and an abrogated hypertrophy response to AngII infusion. It is conceivable that β-catenin works in a similar way to SmgGDS in this model, and that similar result could be obtained with β-catenin–mutant mice. Currently, we are developing SmgGDS-overexpressing mice, which we expect would display phenotypes similar to Rac1-deficient mice and β-catenin–stabilized mice.

In the present clinical protocol with normal healthy volunteers, we were able to demonstrate that regular-dose statins significantly increased SmgGDS expression with a significant negative correlation between SmgGDS expression and oxidative stress markers, whereas no such correlation was noted with total or LDL-cholesterol. The present results are consistent with a previous report that statins inhibit ROS production through inhibition of Rac1 activity in the failing human heart. It has recently been shown that Rac1 also contributes to the pathogenesis of atrial fibrillation through activation of superoxide production, which is inhibited by statins through inhibition of Rac1 activation. In this study, we examined the SmgGDS expression level in polymorphonuclear leukocytes, because it is difficult to obtain blood vessels from human subjects. However, the present method is widely accepted as a method to evaluate the small GTP-binding proteins activity in cardiovascular system. Moreover, because statins significantly reduced the serum levels of total cholesterol and LDL-cholesterol even in the normolipidemic volunteers, a consistent finding with previous reports, we cannot completely rule out the possible involvement of their cholesterol-lowering effect in the present results in humans. Furthermore, the present findings in healthy volunteers remain to be confirmed in patients with cardiovascular disease (eg, coronary artery disease, hypertension, and heart failure).

Based on our previous findings, the doses of statins required to inhibit Rac1 signaling are 3-fold higher than those required to inhibit Rac1 signaling. Therefore, we consider that >60 mg/d atorvastatin is needed to partially inhibit Rac1 activity and raltegravir, a selective Rac1 inhibitor, should be more effective than raltegravir alone for ameliorating AngII-induced cardiovascular hypertrophy in vivo. Indeed, to avoid adverse effects of statins (eg, rhabdomyolysis and diabetes mellitus), we recommend that combination therapy with a statin and a Rho-kinase inhibitor be used rather than monotherapy with a high-dose statin (Figure 6). Further understanding of the molecular mechanisms of the pleiotropic effects of statins will allow us to select appropriate therapies for patients. Excessive increase in SmgGDS expression may enhance its guanine nucleotide exchange factor function and, in turn, may cause the adverse effects of high-dose statins, which are still poorly understood. Activation of the guanine nucleotide exchange factor function of SmgGDS may explain the adverse effects by high-dose statins. Our present finding of the novel mechanisms of actions of statins through enhancement of Rac1 degradation, in addition to inhibition of mevalonate and Rho/Rho-kinase pathways, may have significant impacts on the current use of statins and the development of new cardiovascular drugs.

**Acknowledgments**

We thank A. Saito, C. Miyamoto, and T. Hiroi for excellent technical assistance and Asahi-Kasei Pharma, Pfizer, Kowa Pharmaceutical, and Daiichi Sankyo, Co, Tokyo, Japan, for providing hydroxyfasudil, atorvastatin, pitavastatin, and pravastatin, respectively.

**Sources of Funding**

This work was supported in part by the Grant-in-Aid for Scientific Research on Innovative Areas (Signaling Functions of Reactive
Oxygen Species), the Grant-in-Aid for Tohoku University Global COE for Conquest of Signal Transduction Diseases with Network Medicine, and the Grants-in-Aid for Scientific Research; all of which are from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan.

Disclosures
None.

References
32. Tanaka et al SmgGDS in the Pleiotropic Effects of Statins 1599
Statins are widely used in billions of patients for primary and secondary prevention of cardiovascular diseases. There are 2 known mechanisms of statins, including the inhibition of cholesterol synthesis in the liver and that of geranylgeranyl pyrophosphate pathway with resultant inhibition of small G proteins. We have previously demonstrated that the cholesterol-independent, pleiotropic effects of regular doses of statins are mediated mainly through inhibition of the Rac1 pathway rather than the Rho/Rho-kinase pathway, although the molecular mechanisms of the selective inhibition of the Rac1 pathway remain to be elucidated. In this study, we were able to demonstrate the novel and the third mechanism of statins, by which they upregulate small GTP-binding protein dissociation stimulator with resultant selective degradation of Rac1 in animals and humans. Our findings may have significant impacts on our understanding of the cardiovascular effects of statins and the development of new class of cardiovascular drugs.
Statins Exert the Pleiotropic Effects Through Small GTP-Binding Protein Dissociation Stimulator Uregulation With a Resultant Rac1 Degradation
Shin-ichi Tanaka, Yoshihiro Fukumoto, Kotaro Nochioka, Tatsuro Minami, Shun Kudo, Nobuyuki Shiba, Yoshimi Takai, Carol L. Williams, James K. Liao and Hiroaki Shimokawa

Arterioscler Thromb Vasc Biol. 2013;33:1591-1600; originally published online May 2, 2013; doi: 10.1161/ATVBAHA.112.300922
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/33/7/1591

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2013/05/02/ATVBAHA.112.300922.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org/subscriptions/
Supplemental Material

Statins Exert the Pleiotropic Effects through SmgGDS Up-regulation with a Resultant Rac1 Degradation

Shin-ichi Tanaka, Yoshihiro Fukumoto, Kotaro Nochioka, Tatsuro Minami, Shun Kudo, Nobuyuki Shiba, Yoshimi Takai, Carol L. Williams, James K. Liao, Hiroaki Shimokawa
Supplemental Figure I. Statins Up-regulate SmgGDS in HCAEC.

(A, B) Expression of SmgGDS protein after incubating HCAEC with atorvastatin (ATOR) or pitavastatin (PITA) for 24h ($n$=3 each). Results are expressed as mean ± s.e.m.
Supplemental Figure II. eNOS Up-regulation by Statins in HUVEC is Reversed by Inhibition of PI3K/Akt Pathway

(A, B) The effect of LY294002 (10 µmol/L), MK2206 (10 µmol/L) and Akt1/2 inhibitor (AKT1/2i, 10 µmol/L) on statin-induced eNOS up-regulation in HUVEC (n=3). Results are expressed as mean ± s.e.m.
Supplemental Figure III. eNOS Up-regulation by Statins in HUVEC is Reversed by Inhibition of Mevalonate Pathway

(A) The effect of mevalonate (200 µmol/L) on statin-induced eNOS up-regulation in HUVEC (n=3).

(B) The effect of farnesyl pyrophosphate (FPP, 10µmol/L) and geranylgeranyl pyrophosphate (GGPP, 10µmol/L) on statin-induced eNOS up-regulation in HUVEC (n=3). Results are expressed as mean ± s.e.m.
Supplemental Figure IV. SmgGDS siRNA Abolishes Rac1 Degradation and Anti-oxidant Effects of Pitavastatin in HUVEC.

(A) Western blot analysis of total cell lysate of HUVEC transfected with mock or SmgGDS siRNA for 72h. Pitavastatin was added during the last 24h (n=3). (B) The effect of proteasome inhibitor (MG-132) on pitavastatin-induced Rac1 reduction in the nuclear fraction (n=3). (C) Representative dichlorofluorescein (DCF) staining of HUVEC after pre-incubation with pitavastatin (0.1 µmol/L) for 24h followed by 3h incubation with 1 µmol/L AngII. (D) Densitometric analysis (n=8). Results are expressed as mean ± s.e.m.
Supplemental Figure V. Protein Expression Level in the Cytosolic and Nuclear Fractions in HUVEC.

(A) Western blot analysis of cytosol fraction of HUVEC after the treatment of proteasome inhibitor (MG-132) (n=3). (B) Western blot analysis of total cell lysate of HUVEC transfected with mock or SmgGDS siRNA for 72h. Atorvastatin was added during the last 24h (n=3). (C) Western blot analysis of nuclear fraction of HUVEC after the treatment of proteasome inhibitor (MG-132) (n=3). Results are expressed as mean ± s.e.m.
Supplemental Figure VI. Flow Diagram of the Human Study.

The present clinical study was conducted in a cross-over manner with atorvastatin and pravastatin in 20 normal volunteers with a 2-week washout period.
Supplemental Table I.  Body Weight, Blood Pressure and Plasma Lipid Profiles of Mice.

<table>
<thead>
<tr>
<th></th>
<th>SmgGDS&lt;sup&gt;+/+&lt;/sup&gt;</th>
<th>SmgGDS&lt;sup&gt;+/&lt;/sup&gt;/</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>AngII (+)</td>
<td>AngII+ ATOR (10 mpk)</td>
</tr>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28.2±1.0</td>
<td>28.2±1.0</td>
<td>28.2±1.0</td>
<td>27.5±1.1</td>
</tr>
<tr>
<td>28.2±1.0</td>
<td>28.2±1.0</td>
<td>28.2±1.0</td>
<td>27.5±1.1</td>
</tr>
<tr>
<td>27.5±1.1</td>
<td>28.2±0.7</td>
<td>29.4±0.6</td>
<td>27.8±0.8</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>119.5±3.6</td>
<td>154.5±7.3*</td>
<td>146.7±7.6</td>
<td>141.0±7.3</td>
</tr>
<tr>
<td>119.5±3.6</td>
<td>154.5±7.3*</td>
<td>146.7±7.6</td>
<td>141.0±7.3</td>
</tr>
<tr>
<td>113.8±21.5</td>
<td>98.3±7.7</td>
<td>111.2±6.8</td>
<td>84.8±5.8</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>91.2±2.7</td>
<td>113.8±21.5</td>
<td>98.3±7.7</td>
<td>111.2±6.8</td>
</tr>
<tr>
<td>91.2±2.7</td>
<td>113.8±21.5</td>
<td>98.3±7.7</td>
<td>111.2±6.8</td>
</tr>
<tr>
<td>LDL-cholesterol (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.7±0.9</td>
<td>16.2±4.4</td>
<td>13.7±6.6</td>
<td>16.1±2.3</td>
</tr>
<tr>
<td>10.7±0.9</td>
<td>16.2±4.4</td>
<td>13.7±6.6</td>
<td>16.1±2.3</td>
</tr>
<tr>
<td>HDL-cholesterol (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74.2±3.4</td>
<td>88.3±14.3</td>
<td>76.3±6.8</td>
<td>88.0±4.5</td>
</tr>
<tr>
<td>74.2±3.4</td>
<td>88.3±14.3</td>
<td>76.3±6.8</td>
<td>88.0±4.5</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52.5±8.3</td>
<td>54.2±17.9</td>
<td>67.8±11.0</td>
<td>47.3±10.9</td>
</tr>
<tr>
<td>52.5±8.3</td>
<td>54.2±17.9</td>
<td>67.8±11.0</td>
<td>47.3±10.9</td>
</tr>
<tr>
<td>52.5±8.3</td>
<td>54.2±17.9</td>
<td>67.8±11.0</td>
<td>47.3±10.9</td>
</tr>
</tbody>
</table>

Results are presented as mean±s.e.m.  (n=10 each).  AngII, angiotensinII; ATOR, atorvastatin; PRA, pravastatin; LDL, low-density lipoprotein; HDL, high-density lipoprotein.  *P<0.05 vs. control.
### Supplemental Table II. Baseline Characteristics of 20 Participants in the Human Study.

<table>
<thead>
<tr>
<th></th>
<th>Total (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>30.9 ± 0.7</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>16 (80%)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>4 (20%)</td>
</tr>
<tr>
<td><strong>Body weight (kg)</strong></td>
<td>68.2 ± 2.4</td>
</tr>
<tr>
<td><strong>Blood pressure</strong></td>
<td></td>
</tr>
<tr>
<td>Systolic (mmHg)</td>
<td>124.6 ± 2.2</td>
</tr>
<tr>
<td>Diastolic (mmHg)</td>
<td>77.5 ± 1.5</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>72.2 ± 2.3</td>
</tr>
</tbody>
</table>

Results are presented as mean ± s.e.m.
Supplemental Table III. Effects of Statins on Plasma Lipid Profiles, Glucose, Insulin and HOMA-IR.

<table>
<thead>
<tr>
<th></th>
<th>Pravastatin 20 mg/day</th>
<th>Atorvastatin 20 mg/day</th>
<th>P value</th>
<th>Pravastatin 20 mg/day</th>
<th>Atorvastatin 20 mg/day</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After 2 weeks</td>
<td>Change</td>
<td>Baseline</td>
<td>After 2 weeks</td>
<td>Change</td>
</tr>
<tr>
<td>Fasting lipids (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>192±4.5</td>
<td>165±4.5</td>
<td>-14</td>
<td>197±5.0</td>
<td>138±3.8</td>
<td>-30</td>
</tr>
<tr>
<td>LDL-cholesterol</td>
<td>116±4.5</td>
<td>88±4.0</td>
<td>-24</td>
<td>118±4.3</td>
<td>64±3.4</td>
<td>-46</td>
</tr>
<tr>
<td>HDL-cholesterol</td>
<td>58±2.7</td>
<td>61±2.8</td>
<td>5</td>
<td>60±2.9</td>
<td>60±2.7</td>
<td>0</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>103±12.9</td>
<td>87±9.1</td>
<td>-16</td>
<td>109±9.9</td>
<td>73±6.5</td>
<td>-33</td>
</tr>
<tr>
<td>RLP-cholesterol</td>
<td>4.1±0.5</td>
<td>3.2±0.3</td>
<td>-22</td>
<td>4.0±0.3</td>
<td>2.6±0.1</td>
<td>-35</td>
</tr>
<tr>
<td>MDA-LDL (U/L)</td>
<td>113±9.6</td>
<td>85±6.7</td>
<td>-25</td>
<td>118±10.6</td>
<td>73±4.5</td>
<td>-38</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>96±1.4</td>
<td>99±1.3</td>
<td>3</td>
<td>97±1.3</td>
<td>98±1.5</td>
<td>1</td>
</tr>
<tr>
<td>Insulin (μ IU/mL)</td>
<td>9.4±1.1</td>
<td>8.4±0.9</td>
<td>-11</td>
<td>8.8±0.8</td>
<td>8.3±0.5</td>
<td>-6</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.2±0.3</td>
<td>2.1±0.2</td>
<td>5</td>
<td>2.1±0.2</td>
<td>2.0±0.1</td>
<td>-5</td>
</tr>
</tbody>
</table>

Results are presented as mean ± s.e.m. (n=20 each).

LDL, low-density lipoprotein; HDL, high-density lipoprotein; RLP, remnant like particle; HOMA-IR, homeostasis model assessment-insulin resistance.
Materials and Methods

Statins Exert the Pleiotropic Effects through SmgGDS Up-regulation with a Resultant Rac1 Degradation

Shin-ichi Tanaka, Yoshihiro Fukumoto, Kotaro Nochioka, Tatsuro Minami, Shun Kudo, Nobuyuki Shiba, Yoshimi Takai, Carol L. Williams, James K. Liao, Hiroaki Shimokawa
Cell Culture and Drug Treatment

Human umbilical venous endothelial cells (HUVEC) (Takara Bio Inc., Otsu, Japan) were incubated at 37˚C in 5% CO₂ in endothelial growth medium (EGM-2, Lonza) for 1 day, and then the cells were treated with different concentrations (1-30 μmol/L) of statins, including atorvastatin (Pfizer), pitavastatin (Kowa Pharmaceutical) and pravastatin (Daiichi-Sankyo), GSK-3β inhibitor (SB216763, Sigma) or Rho-kinase inhibitor (hydroxyfasudil) for 24h. We co-treated HUVEC with statins and PI3K inhibitor (LY294002, Sigma), Akt inhibitor (MK-2206, Selleck chemicals), Akt1/2 inhibitor (AKT1/2i, Sigma) (Sigma), mevalonate (Sigma), farnesyl pyrophosphate (Sigma) or geranylgerany pyrophosphate (Sigma) for 24h or a proteasome inhibitor MG-132 (Calbiochem) for 14h. After the treatment with each drug, the cells were washed twice with ice-cold phosphate-buffered saline and sonicated after adding lysis buffer. The nuclear fractionation was performed using the Qproteome cell compartment kit (Qiagen).

Western Blot Analysis

To quantify the expression levels of RhoA, Rac1 and SmgGDS in HUVEC, murine aorta and in human polymorphonuclear leukocytes (PMNL), an equal number of protein samples were loaded on SDS-PAGE gel and transferred to PVDF membranes (GE Healthcare). The membranes were immunoblotted with anti-RhoA (Santa Cruz), anti-Rac1 (Millipore), anti-K-Ras (Santa Cruz), anti-SmgGDS (BD transduction Lab.), anti-VEGF (Abcam), anti-eNOS (BD transduction Lab.), anti-β-actin (Sigma), and anti-LAMIN A/C (BD transduction Lab.). After incubating with horseradish-peroxidase-conjugated rabbit anti-mouse, goat anti-rabbit or donkey anti-goat IgG antibody, blots were visualized by the enhanced chemiluminescence system (ECL Western Blotting Detection Kit, GE Healthcare). Densitometric analysis was performed by Image J (NIH) Software.

Transfection of HUVEC with siRNA

Multiple siRNA duplexes for SmgGDS were purchased from Qiagen. Multiple siRNA duplexes were transfected and tested for maximal and specific suppression of their target
protein as previously described. A functional non-targeting siRNA that was bioinformatically designed by Qiagen was used as a control. HUVEC were transfected with HiPerFect Transfection Reagent (Qiagen) with either 10 nmol/L mock siRNA or 10 nmol/L siRNA specific for SmgGDS. After 72h post-transfection, the cells were analyzed by Western blot or ROS analysis.

**Reactive Oxygen Species Analysis**

Intracellular ROS production in HUVEC was measured as previously described. We treated HUVEC with AngII (1 μmol/L, Wako) for 3h at 37°C in 5% CO₂, washed them with PBS and loaded them with 2,7-dichlorofluorescein diacetate (H2DCF-DA) (5 μmol/L, Cayman) for 30 min at 37°C to reveal the presence of ROS as green fluorescence (488 nm) by fluorescence microscopy (BIOREVO, Keyence). The relative fluorescence intensity was measured by BZ-II analyzer (Keyence) software.

**Analysis of Medial Thickening and Perivascular Fibrosis of Mouse Coronary Arteries**

We conducted all mouse experiments in accordance with experimental protocols that were approved by the Animal Care and Use Committee of the Tohoku University Graduate School of Medicine. We used the AngII-infused cardiovascular hypertrophy model to assess the effect of SmgGDS deficiency on the pleiotropic effects of regular-dose statins. We infused AngII (2.0 mg/kg/day) or saline for 2 weeks in 10-week-old male SmgGDS⁺/⁻ littermate control mice and SmgGDS⁺/⁺ mice. We dissolved AngII in sterile saline and infused it via an osmotic mini-pump (Alzet model 2002, Alze Corp.). We anesthetized the animals with isofluorane and placed the pump into the subcutaneous space of isofluorane-anesthetized mice through a small incision in the back that was closed by suturing. Both the AngII-infused and saline-infused mice were administrated either statin or placebo treatment by gavage every day for 2 weeks. All incision sites healed rapidly without any infection. Systolic blood pressure was measured using a non-invasive tail-cuff system (MK-2000, Muromachi) at 2 weeks after pump implantation. Plasma lipids (triglycerides, total cholesterol, and LDL- and HDL-cholesterol) were analyzed with high-performance liquid chromatography system by
Skylight Biotech. Histological studies were performed for the determination of medial thickness and fibrosis of coronary arteries, as previously reported.\textsuperscript{4,5}

**Human Study**

This protocol was approved by the Human Research Committee of the Tohoku University Graduate School of Medicine, and 20 normal healthy human volunteers participated after written consent was obtained (Supplemental Table II). The volunteers received pravastatin (20 mg/day) or atorvastatin (20 mg/day) orally for 2 weeks in a randomized cross-over manner with a 2-week washout interval. The 2-week interval is enough to restore lipid profiles to pre-statin treatment levels.\textsuperscript{6} Leukocytes were isolated according to the method previously described with slight modification.\textsuperscript{7}

**Statistical Analysis**

Comparisons of parameters between two groups were performed with the unpaired Student’s t-test. Statistical analysis was performed by one-way ANOVA followed by Dunnett’s test for multiple comparisons. Statistical significance was evaluated with JMP 8 (SAS Institute). A \( P \) value of <0.05 was considered to be statistically significant.
Materials and Methods References


